Release date of annual report 2022 for ALK and audio cast
On Friday, 3 February 2023 expectedly around noon, ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its annual report for 2022.
ALK will host a meeting for analysts and institutional investors that day at 2.00pm (CET) at which Management will review the financial results, the outlook and answer questions.
The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins.
Participants in the conference call are kindly requested to call in before 1.55pm (CET). Danish participants should call in on tel. +45 7877 4197 and international participants should call in on tel. +44 0 808 101 1183 or +1 785 424 1739. Please use the following participant pin code: 91630#
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Upcoming Life Sciences Events
- March 2023
- Zurich: Swiss Nordic Bio 2023
- April 2023
- Basel: Swiss Biotech Day 2023
- Brussels: Cell and Gene Therapy Summit
Latest company news
Freeline Therapeutics to Host Full Year 2022 Financial Results Call
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
Asia Pacific Mammography Devices Market Analysis Report 2022: Focus on China, India, Japan, South Korea, Australia, New Zealand, Malaysia, Vietnam, Indonesia, & Singapore